Oral candidiasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Oral candidiasis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Refli..." |
m Bot: Removing from Primary care |
||
| (24 intermediate revisions by 7 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Oral candidiasis}} | {{Oral candidiasis}} | ||
{{CMG}};{{AE}}{{AY}} | |||
==Overview== | |||
Oral candidiasis can be treated with topical [[anti-fungal]] drugs, such as [[nystatin]] (mycostatin), [[miconazole]] or [[amphotericin B]]. Patients who are [[immunocompromised]], either with [[HIV]]/[[AIDS]] or as a result of [[chemotherapy]], may require systemic treatment with oral or intravenous administered [[Antifungal drug|antifungals]]. | |||
==Medical Therapy== | |||
Any underlying cause, such as poor glucose control in [[diabetics]], should be addressed. Oral candidiasis can be treated with topical [[anti-fungal]] drugs, such as [[nystatin]] (mycostatin), [[miconazole]] or [[amphotericin B]]. Patients who are [[immunocompromised]], either with [[HIV]]/[[AIDS]] or as a result of [[chemotherapy]], may require systemic treatment with oral or intravenous administered [[antifungals]]. | |||
Oral candidiasis usually responds to topical treatments such as [[clotrimazole]] troches and [[nystatin]] suspension ([[nystatin]] - swish and swallow). Systemic [[Antifungal drug|antifungal medication]] such as [[fluconazole]] or [[itraconazole]] may be necessary for oropharyngeal infections that do not respond to these treatments. | |||
===Treatment Regimen=== | |||
*'''Oropharyngeal candidiasis'''<ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635 }} </ref> | |||
:*Preferred regimen: [[Clotrimazole]] troches 10 mg TOP q4-5h {{or}} [[Nystatin]] suspension or pastilles TOP q6h {{or}} [[Fluconazole]] 100–200 mg PO q24h | |||
:*Alternative regimen: [[Itraconazole]] solution 200 mg PO q24h {{or}} [[Posaconazole]] 400 mg PO q24h {{or}} [[Voriconazole]] 200 mg PO q24h {{or}} [[Amphotericin B]] oral suspension PO q24h {{or}} ([[Anidulafungin]] 200 mg IV once <u>'''THEN'''</u> [[Anidulafungin]] 100 mg IV q24h) {{or}} ([[Caspofungin]] 70 mg IV once <u>'''THEN'''</u> [[Caspofungin]] 50 mg IV q24h) {{or}} [[Micafungin]] 100 mg IV q24h {{or}} [[Amphotericin B]] 0.3 mg/kg IV q24h | |||
:*Note: Treat uncomplicated disease for 7–14 days. [[Fluconazole]] is recommended in moderate-to-severe disease, and topical therapy with [[Clotrimazole]] or [[Nystatin]] is recommended for mild disease. For refractory disease, consider the alternative regimen. | |||
*'''Medical treatment of oropharyngeal candidiais in immunocompromised patients:'''<ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635 }} </ref> | |||
Most [[immunocompromised]] patients respond initially to topical agents using the same regimen above but relapses occur rapidly unless [[fluconazole]] (400 mg [6 mg/kg} daily)is not used. | |||
:*In pediatric patients: use [[itraconazole]] in a dose of 2.5 mg/kg/day. | |||
:*Continuous prophylactic [[fluconazole]] use is more effective than intermittent use in response to relapses. | |||
:*In [[fluconazole]] resistant cases: [[Itraconazole]] (200 mg twice daily) can be used with cure rate between 64 - 80% | |||
:*[[Posaconazole]] (200 mg 3 times daily) can be used with cure rate of 80% | |||
:*[[Caspofungin|Intravenous caspofungin]] (200 mg 3 times daily), [[micafungin]] (50 mg daily), or [[anidulafungin]] (loading dose of 200 mg and 100 mg daily) can be used as alternatives to [[triazoles]]. | |||
==Videos== | |||
* Treatment | |||
{{#ev:youtube|msqtXBteGY8}} | |||
* Treatment in Newborn: | |||
{{#ev:youtube|DPdAG8aJ9u4}} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Disease]] | |||
[[Category:Fungal diseases]] | [[Category:Fungal diseases]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Emergency mdicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category: | [[Category:Otolaryngology]] | ||
[[Category:Pediatrics]] | |||
[[Category:Immunology]] | |||
Latest revision as of 23:00, 29 July 2020
|
Oral candidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oral candidiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Oral candidiasis medical therapy |
|
Risk calculators and risk factors for Oral candidiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]
Overview
Oral candidiasis can be treated with topical anti-fungal drugs, such as nystatin (mycostatin), miconazole or amphotericin B. Patients who are immunocompromised, either with HIV/AIDS or as a result of chemotherapy, may require systemic treatment with oral or intravenous administered antifungals.
Medical Therapy
Any underlying cause, such as poor glucose control in diabetics, should be addressed. Oral candidiasis can be treated with topical anti-fungal drugs, such as nystatin (mycostatin), miconazole or amphotericin B. Patients who are immunocompromised, either with HIV/AIDS or as a result of chemotherapy, may require systemic treatment with oral or intravenous administered antifungals.
Oral candidiasis usually responds to topical treatments such as clotrimazole troches and nystatin suspension (nystatin - swish and swallow). Systemic antifungal medication such as fluconazole or itraconazole may be necessary for oropharyngeal infections that do not respond to these treatments.
Treatment Regimen
- Oropharyngeal candidiasis[1]
- Preferred regimen: Clotrimazole troches 10 mg TOP q4-5h OR Nystatin suspension or pastilles TOP q6h OR Fluconazole 100–200 mg PO q24h
- Alternative regimen: Itraconazole solution 200 mg PO q24h OR Posaconazole 400 mg PO q24h OR Voriconazole 200 mg PO q24h OR Amphotericin B oral suspension PO q24h OR (Anidulafungin 200 mg IV once THEN Anidulafungin 100 mg IV q24h) OR (Caspofungin 70 mg IV once THEN Caspofungin 50 mg IV q24h) OR Micafungin 100 mg IV q24h OR Amphotericin B 0.3 mg/kg IV q24h
- Note: Treat uncomplicated disease for 7–14 days. Fluconazole is recommended in moderate-to-severe disease, and topical therapy with Clotrimazole or Nystatin is recommended for mild disease. For refractory disease, consider the alternative regimen.
- Medical treatment of oropharyngeal candidiais in immunocompromised patients:[1]
Most immunocompromised patients respond initially to topical agents using the same regimen above but relapses occur rapidly unless fluconazole (400 mg [6 mg/kg} daily)is not used.
- In pediatric patients: use itraconazole in a dose of 2.5 mg/kg/day.
- Continuous prophylactic fluconazole use is more effective than intermittent use in response to relapses.
- In fluconazole resistant cases: Itraconazole (200 mg twice daily) can be used with cure rate between 64 - 80%
- Posaconazole (200 mg 3 times daily) can be used with cure rate of 80%
- Intravenous caspofungin (200 mg 3 times daily), micafungin (50 mg daily), or anidulafungin (loading dose of 200 mg and 100 mg daily) can be used as alternatives to triazoles.
Videos
- Treatment
{{#ev:youtube|msqtXBteGY8}}
- Treatment in Newborn:
{{#ev:youtube|DPdAG8aJ9u4}}
References
- ↑ 1.0 1.1 Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE; et al. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635.